Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vpriv Generic Name & Formulations
Legal Class
Rx
General Description
Velaglucerase alfa 400 Units/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Pharmacological Class
Lysosomal glucocerebroside-specific enzyme.
How Supplied
Single-use vial—1
Manufacturer
Generic Availability
NO
Vpriv Indications
Indications
Long-term enzyme replacement therapy (ERT) in patients with Type 1 Gaucher disease.
Vpriv Dosage and Administration
Adults and Children
<4yrs: not established. Give by IV infusion over 60mins. Individualize. ≥4yrs: 60 Units/kg every other week; adjust dose based on therapeutic goals. Begin treatment with Vpriv at the same dose when switching from imiglucerase.
Vpriv Contraindications
Not Applicable
Vpriv Boxed Warnings
Not Applicable
Vpriv Warnings/Precautions
Warnings/Precautions
Have medical support and resuscitative measures readily available. Discontinue immediately and treat if anaphylactic or other acute reactions occur. Temporarily discontinue and resume with increased infusion time, slowing infusion rate, or administer antihistamines, antipyretics, and/or corticosteroids if hypersensitivity reactions occur. Elderly. Pregnancy. Nursing mothers.
Vpriv Pharmacokinetics
See Literature
Vpriv Interactions
Not Applicable
Vpriv Adverse Reactions
Adverse Reactions
Hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, activated PTT prolonged, fatigue/asthenia, pyrexia.
Vpriv Clinical Trials
See Literature
Vpriv Note
Not Applicable
Vpriv Patient Counseling
See Literature
